Overview

Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer

Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
We postulate that multiple apoptototic events are indusce through testosterone depletion and repletion with taxotere given in conjunction with androgen withdrawal.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Treatments:
Docetaxel
Leuprolide
Testosterone